natgillin/translations-raw huggingface dataset:
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A and parvovirus B19 viruses.
Privzeti ukrepi se štejejo za učinkovite proti virusom z ovojnico, kakršni so virus človeške imunske pomanjkljivosti (HIV), virus hepatitisa B in virus hepatitisa C, ter proti virusom brez ovojnice, kakršna sta virusa hepatitisa A in parvovirus B19.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A virus and parvovirus B19.
Ukrepi so učinkoviti proti virusom z ovojnico, kot so virus imunske pomanjkljivosti (HIV), virusa hepatitisa B in C, ter za viruse brez ovojnice – virus hepatitisa A in viruse B19.
The measures taken are considered effective for the following viruses: human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, hepatitis A virus and parvovirus B19.
Ti ukrepi se smatrajo za učinkovite v primeru naslednjih virusov: virus človeške imunske pomanjkljivosti (HIV), virus hepatitisa B, virus hepatitisa C, virus hepatitis A in parvovirus B19.
The measures taken may be of limited value against non-enveloped viruses as hepatitis A virus and parvovirus B19 (causing fifth disease).
Ukrepi, ki se izvajajo, so morda manj učinkoviti proti virusom brez ovojnice, kot sta virus hepatitisa A in parvovirus B19.
The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.
Ti ukrepi pa imajo lahko le omejeno vrednost proti virusom brez ovojnice, kot je parvovirus B19.
The measures taken to ensure the safe use of Omnitrope are linked to the reasons why the medicine is used.
Ukrepi, sprejeti za zagotovitev varne uporabe zdravila Omnitrope, so povezani z razlogi za uporabo zdravila.
The measuring jug in the pack has a line marked to show you an exact amount.
Merilna čaša, ki je priložena v škatli z zdravilom, ima oznako, ki prikazuje pravo količino.
The mechanism behind the increased incidence of atrial fibrillation in this single clinical trial is unknown.
Mehanizem, na katerem temelji zvišana incidenca atrijske fibrilacije v tem edinem kliničnem preskušanju, ni znan.
The mechanism behind the increased incidence of atrial fibrillation is unknown.
Mehanizem, na katerem temelji višja incidence atrijske fibrilacije, ni znan.
The mechanism by which Ceplene improves the anti-leukaemic function of lymphocytes in AML is not completely established; it is considered to be by inhibition of reactive oxygen species (ROS or ‘oxygen free radicals’), which are synthesised by monocytes/macrophages and granulocytes.
Mehanizem, s katerim zdravilo Ceplene izboljšuje protilevkemično delovanje limfocitov pri akutni mieloični levkemiji, še ni v celoti dognan, vendar naj bi zaviral reaktivne kisikove vrste (ROS - reactive oxygen species ali kisikovi prosti radikali), ki jih sintetizirajo monociti/makrofagi in granulociti.
The mechanism has not been elucidated.
Mehanizem ni razjasnjen.
The mechanism is UGT1A1
Mehanizem je zaviranje UGT1A1
The mechanism of action by which bimatoprost reduces intraocular pressure in humans is by increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral outflow.
Mehanizem delovanja, s katerim bimatoprost znižuje zvišan očesni tlak pri ljudeh, je povečanje iztekanja prekatne vodice skozi trabekularno omrežje in povečanje uveoskleralnega iztekanja.
The mechanism of action in indications other than replacement therapy is not fully elucidated, but includes immunomodulatory effects.
Mehanizem delovanja pri indikacijah (razen nadomestnega zdravljenja) ni popolnoma raziskan, vendar vključuje imunomodulacijske učinke.
The mechanism of action in indications other than replacement therapy is not fully elucidated, but includes immunomodulatory effects.
Mehanizem delovanja pri indikacijah, ki niso del nadomestnega zdravljenja, ni v celoti pojasnjen, vendar vključuje učinke imunomodulacije.
The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA synthesis.
Načina delovanja ne razumemo v celoti, vendar kaže, da ara-CTP deluje predvsem preko zaviranja sinteze DNA.
The mechanism of action of belimumab could increase the risk for the development of infections, including opportunistic infections.
Zaradi svojega mehanizma delovanja lahko belimumab poveča tveganje okužb, vključno z oportunističnimi okužbami.
The mechanism of action of Holoclar is the replacement of corneal epithelium and lost limbal stem cells in patients in which the limbus has been destroyed by ocular burns.
Mehanizem delovanja zdravila Holoclar je nadomestitev roženičnega epitelija in izgubljenih limbusnih matičnih celic pri bolnikih, pri katerih je bil limbus uničen ob opeklini očesa.
The mechanism of action of ingenol mebutate for use in actinic keratosis remains to be fully characterised.
Mehanizem delovanja ingenol mebutata pri aktinični keratozi še ni popolnoma pojasnjen.
The mechanism of action of Japanese encephalitis (JE) vaccines is not well understood.
Mehanizma delovanja cepiv proti virusu japonskega encefalitisa (JE) ne razumemo dobro.
The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves inhibition of bacterial DNA gyrase and topoisomerase IV enzymes.
Mehanizem delovanja levofloksacina in drugih fluorokonolonskih protimikrobnih zdravil vključuje zaviranje bakterijske DNA giraze in encimov topoizomeraze IV.
The mechanism of action of pirfenidone has not been fully established.
Mehanizem delovanja pirfenidona še ni bil popolnoma ugotovljen.
The mechanism of action of pirfenidone, the active substance in Esbriet, is not fully understood, but it has been shown to reduce the production of fibroblasts and other substances involved in the formation of hard fibrous tissue during the body’s tissue repair process, thereby slowing down the progression of the disease in IPF patients.
Mehanizem delovanja zdravilne učinkovine zdravila Esbriet, pirfenidona, še ni popolnoma znan, vendar je bilo ugotovljeno, da zmanjšuje tvorbo fibroblastov in drugih snovi, ki vplivajo na oblikovanje trdega fibroznega tkiva med procesom obnavljanja tkiv, ter tako upočasnjuje napredovanje bolezni pri bolnikih z idiopatsko pljučno fibrozo.
The mechanism of action of tacrolimus in atopic dermatitis is not fully understood.
Mehanizem delovanja takrolimusa pri atopičnem dermatitisu ni povsem jasen.
The mechanism of blood glucose lowering also involves a minor delay in gastric emptying.
Mehanizem zniževanja koncentracije glukoze v krvi vključuje tudi manjšo upočasnitev praznjenja želodca.
The mechanism of interaction
Mehanizem interakcije med
The mechanism of interaction between atazanavir and tenofovir disoproxil fumarate is unknown.
Mehanizem interakcije med atazanavirjem in dizoproksiltenofovirat fumaratom ni znan.
The mechanism of interaction is
Mehanizem interakcije je
The mechanism of interaction is
Mehanizem interakcije je manjša
The mechanism of interaction is
Mehanizem interakcije je možno
The mechanism of interaction is
Mehanizem interakcije ni znan.
The mechanism of interaction is a
Mehanizem te interakcije je
The mechanism of interaction is CYP3A4 inhibition by atazanavir and cobicistat.
Mehanizem interakcije je zaviranje CYP3A4 z atazanavirjem in kobicistatom.
The mechanism of interaction is CYP3A4 inhibition by atazanavir/ritonavir.
Mehanizem interakcije je zaviranje CYP3A4 z atazanavirjem in/ali ritonavirjem.
The mechanism of interaction is CYP3A4 inhibition by cobicistat.
Mehanizem interakcije je zaviranje CYP3A4 s kobicistatom.
The mechanism of interaction is CYP3A4 inhibition by fosamprenavir/ritonavir.
Mehanizem interakcije je inhibicija CYP3A4 s fosamprenavirjem/ritonavirjem.
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2 blockers.
Mehanizem interakcije je zmanjšana topnost atazanavirja zaradi zvišane vrednosti pH želodčnega soka, ki je posledica uporabe antagonista histaminskih receptorjev H2.
The mechanism of interaction is inhibition of CYP3A4 by
Mehanizem interakcije je zaviranje CYP3A4 s
The mechanism of resistance identified was FKS1/FKS2 gene mutation.
Ugotovili so, da rezistenco omogoči mutacija na genih FKS1/FKS2.
The mechanism of the antihypertensive effect of thiazide diuretics is not fully known.
Mehanizem antihipertenzivnega delovanja tiazidnih diuretikov še ni povsem raziskan.
The mechanism of the interaction has not been completely clarified.
Mehanizem interakcije ni povsem pojasnjen.
The mechanism of the LDL lowering effect of simvastatin may involve both reduction of VLDL-C concentration and induction of the LDL receptor, leading to reduced production and increased catabolism of LDL-C.
Mehanizem simvastatinovega učinka zniževanja ravni LDL morda obsega tako znižanje ravni VLDL-holesterola in indukcijo LDL receptorja, kar privede do zmanjšane tvorbe in povečanega katabolizma LDL-holesterola.
The mechanism of this decrease is unknown. (See sections 4.2 and 4.4.)
Mehanizem za to zmanjšanje ni znan. (Glejte poglavji 4.2 in 4.4.)
The mechanism of vasculitis in patients receiving Neulasta is unknown.
Mehanizem vaskulitisa pri bolnikih, ki prejemajo zdravilo Neulasta, ni znan.
The mechanisms and potential mechanisms contributing to the interaction profile of tipranavir are described (see section 4.5).
Opisani so mehanizmi in možni mehanizmi medsebojnega delovanja s tipranavirjem (glejte poglavje 4.5).
The mechanisms and potential mechanisms contributing to the interaction profile of tipranavir are described (see section 4.5).
Opisani so mehanizmi in možni mehanizmi medsebojnega delovanja s tipranavirjem,(glejte poglavje 4.5).
The median (Q1, Q3) change from baseline in total cholesterol to HDL-cholesterol ratio at Week 96 was 0.1 (-0.3, 0.7) in the E/C/F/TAF group and 0.0 (-0.4, 0.5) in the E/C/F/TDF group (p < 0.001 for the difference between treatment groups).
Mediana (Q1, Q3) sprememba od začetne vrednosti za razmerje med skupnim holesterolom in HDL holesterolom v 96. tednu je bila 0,1 (-0,3; 0,7) v skupini z zdravilom E/C/F/TAF in 0,0 (-0,4; 0,5) v skupini z E/C/F/TDF (p < 0,001 za razliko med skupinama zdravljenja).
The median (quartile1, quartile 3) time to achieve haemoglobin correction (≥ 10.0 g/dl and ≥ 1.0 g/dl increase from baseline) was 5 weeks for both once every two week (3, 7 weeks) and once monthly dosing (3, 9 weeks).
Mediani (1. kvartil, 3. kvartil) čas do dosežene odprave anemije (≥ 100 g/l in porast za ≥ 10 g/l od izhodišča) je bil 5 tednov tako med uporabo enkrat na dva tedna (3 tedne, 7 tednov) kot med uporabo enkrat na mesec (3 tedne, 9 tednov).
The median (range) lamivudine and zidovudine tmax values were 0.75 (0.50-2.00) hours and 0.50 (0.25- 2.00) hours respectively.
Srednja vrednost (razpon) tmax lamivudina je bila 0,75 ure (0,50 - 2,00), zidovudina pa 0,50 ure (0,25 - 2,00).
The median (range) lamivudine and zidovudine tmax values were 0.75 (0.50-2.00) hours and 0.50 (0.25-2.00) hours respectively.
Srednja vrednost (razpon) tmax lamivudina je bila 0,75 ure (0,50 - 2,00), zidovudina pa 0,50 ure (0,25 - 2,00).
The median absolute increase in hepatic fat was 6% after both 26 weeks and 78 weeks of treatment, from 1% at baseline, measured by MRS.
Mediana absolutnega povečanja maščob v jetrih, ki se je merilo z MRS, je bila po 26 in 78 tednih zdravljenja 6 % v primerjavi z 1 % na izhodišču.
The median age for all patients was 72 years.
Mediana starosti vseh bolnikov je bila 72 let.
The median age of patients was 61.0 (range: 2584) years.
Mediana starosti bolnic je bila 61,0 let (razpon: 25 do 84 let).
The median age of subjects was 36 years (range: 19-70).
Mediana starost bolnikov je bila 36 let (razpon: 19-70).
The median age was 54 years (22% were 65 years); all patients had an ECOG performance score of 0 or 1; and 3 % had history of brain metastases.
Mediana starost je bila 54 let (22 % je bilo starih  65 let); vsi so imeli stanje zmogljivosti 0 ali 1 po ECOG in 3 % so imeli anamnezo metastaz v možganih.
The median age was 60 years (range: 23-88).
Mediana starost bolnikov je bila 60 let (razpon: 23-88), 64 % bolnikov je bilo moškega spola in
The median age was 62 years (range: 21 to 85) with 34% 65 years of age and 7% 75 years of age.
Mediana starost bolnikov je bila 62 let (razpon: 21 do 85), 34 % bolnikov je bilo starih  65 let, 7 % bolnikov pa  75 let.
The median age was 63 years (range: 39-85) with 44% 65 years of age and 11% 75 years of age.
Mediana starost bolnikov je bila 63 let (razpon: 39-85), 44 % bolnikov je bilo starih  65 let, 11 % bolnikov pa  75 let.
The median age was 68 years (range, 34; 88), 74% were male and 87% were Caucasian.
Mediana starost bolnikov je bila 68 let (razpon, 34; 88), 74% jih je bilo moškega spola in 87% je bilo belcev.
The median age was 69 years (range: 35 to 92 years), 27% patients were
Mediana starost je bila 69 let (razpon: od 35 do
The median age was 7.3 years (range: 1 t o 17.6 y ears) and the median daily dose of stiripentol was 45.4 mg/kg/day (range: 27.1 to 89.3 mg/kg/day) received in two or three divided doses.
Povprečna starost otrok je bila 7,3 leta (razpon: 1 do 17,6 let) povprečni dnevni odmerek stiripentola pa 45,4 mg/kg/dan (razpon: 27,1 do 89,3 mg/kg/dan), prejet v dveh ali treh razdeljenih odmerkih.
The median age was 71 years (range 42-93) and the racial distribution was 77% Caucasian, 10% Asian, 2% Black and 11% other or unknown races.
Mediana starost je bila 71 let (razpon od 42 do 93) in porazdelitev glede na raso je bila 77 % belcev, 10 % azijcev, 2 % črncev in 11 % druge ali neznane rase.
The median age was 77 years and the median creatinine clearance was 61 mL/min.
Mediana starosti je bila 77 let in mediana kreatininskega očistka je bila 61 ml/min.
The median average dose per injection to treat a bleeding episode was 46.07 (interquartile range 32.86-57.03) IU/kg.
Mediana povprečnega odmerka na injekcijo za zdravljenje epizode krvavitve je bila 46,07 (interkvartilni razpon 32,86-57,03) i.e./kg.
The median average dose per injection to treat a bleeding episode was 63.51 (interquartile range, 48.92-99.44) IU/kg.
Mediana povprečnega odmerka na injiciranje za zdravljenje epizode krvavitve je bila 63,51 (interkvartilni razpon 48,92-99,44) i.e./kg.
The median average weekly dose for splenectomised patients was 3 µg/kg and for non-splenectomised patients was 2 µg/kg.
Mediani povprečni tedenski odmerek pri splenektomiranih bolnikih je bil 3 µg/kg in pri nesplenektomiranih 2 µg/kg.
The median baseline plasma HIV-1 RNA was 3.9 log10 copies/ml, and the median baseline CD4 cell count was 385 x 106 cells/l.
Ob začetku je bila mediana vrednost HIV-1 RNK 3,9 log10 kopij/ml, mediano število CD4 celic je bilo 385 x 106 celic/l.
The median bosentan and placebo treatment duration was, respectively, 4.5 days (range 0.5–10.0 days) and 4.0 days (range 2.5-6.5 days).
Mediana trajanja zdravljenja z bosentanom in placebom je bila 4,5 dni (razpon 0,5 - 10,0 dni) oziroma 4,0 dni (razpon 2,5 - 6,5 dni).
The median bosentan and placebo treatment duration was, respectively, 4.5 days (range 0.5–10.0 days) and 4.0 days (range 2.5–6.5 days).
Mediana trajanja zdravljenja z bosentanom in placebom je bila 4,5 dni (razpon 0,5 - 10,0 dni) oziroma 4,0 dni (razpon 2,5 - 6,5 dni).
The median change in CD4 cell count at week 48 was +17 x 106 cells/L, in the on-treatment analysis.
Mediana sprememba v številu celic CD4 v 48. tednu je bila +17 x 106 celic/l v analizi med zdravljenjem.
The median change in CD4+ T cell count from baseline for VIKING-3 based on observed data was 61 cells/mm3 at Week 24 and 110 cells/mm3 at Week 48.
Srednja sprememba vrednosti CD4 + T celic od izhodiščne vrednosti glede na dobljene podatke študije VIKING-3 je bila 61 celic/mm3 po 24. tednih in 110 celic/mm3 po 48. tednih.
The median clearance (CL) of Perjeta was 0.235 litres/day and the median half-life was 18 days.
Mediani očistek (Cl) zdravila Perjeta je bil 0,235 litra/dan, mediani razpolovni čas je bil 18 dni.
The median CrCL in RE-LY was 68.4 mL/min.
V raziskavi RE-LY je bila mediana vrednost CrCl 68,4 ml/min.
The median cumulative dose to treatment discontinuation was more than 1,000 mg/m2 and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks).
Mediani kumulativni odmerek do prekinitve zdravljenja je bil več kot 1.000 mg/m in mediani čas do izginotja zastoja tekočine 16,4 tedna (razpon od 0 do 42 tednov).
The median cumulative dose to treatment discontinuation was more than 1,000 mg/m2 and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks).
Srednji kumulativni odmerek do prekinitve zdravljenja je bil več kot 1000 mg/m2 in srednji čas do izginotja zastoja tekočine 16,4 tedna (razpon od 0 do 42 tednov).
The median cumulative dose to treatment discontinuation was more than 1,000 mg/m² and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks).
Mediani kumulativni odmerek do prekinitve zdravljenja je bil več kot 1.000 mg/m² in mediani čas do izginotja zastoja tekočine 16,4 tedna (razpon od 0 do 42 tednov).
The median daily dose of insulin glargine used prior to hyperglycaemic rescue was 10 units (range 2 to 40 units) at study start and 30 units (range 3 to 230 units) at Week 52.
Mediani dnevni odmerek insulina glargina, uporabljenega pred reševanjem hiperglikemije, je bil 10 enot (razpon: od 2 do 40 enot) na začetku študije in 30 enot (razpon: od 3 do 230 enot) 52. teden.
The median DOR for all subjects was 12.5 months (12.5 months for SLL subjects, and not reached for FL, LPL/WM and MZL subjects).
Mediana DOR za vse osebe je bila 12,5 mesecev (12,5 mesecev za osebe s SLL, ni dosežena za osebe s FL, LPL/WM in MZL).
The median dose at response is approximately 6.0 μg/day and approximately 75% of responsive patients require ≤ 9.6 μg/day.
Mediani odmerek, na katerega se bolniki odzovejo, znaša približno 6,0 µg/dan in približno 75 % odzivnih bolnikov potrebuje  9,6 µg/dan.
The median dose intensity was 36 mg or, 80% of the expected 45 mg dose.
Mediana intenzivnosti odmerka je bila 36 mg ali 80 % pričakovanega 45 mg odmerka.
The median dose of thalidomide was 217 mg and >40% of patients received 9 cycles.
Mediana odmerka talidomida je znašala 217 mg in > 40 % bolnikov je prejelo 9 ciklov.
The median dose per injection to maintain haemostasis during surgery was 58.3 (range 45-102) IU/kg.
Mediana odmerka na injekcijo za ohranitev hemostaze med kirurškim posegom je bila 58,3 (razpon 45 do 102) i.e./kg.
The median dose per injection to treat a bleeding episode was 27.35 (interquartile range 22.73-32.71) IU/kg.
Mediana odmerka na injekcijo za zdravljenje epizode krvavitve je bila 27,35 (interkvartilni razpon 22,73 do 32,71) i.e./kg.
The median dose per injection to treat a bleeding episode was 49.69 (interquartile range 29.41-56.82) IU/kg.
Mediana odmerka na injekcijo za zdravljenje epizode krvavitve je bila 49,69 (interkvartilni razpon 29,41 do 56,82) i.e./kg.
The median dose to treat break-through bleeding episodes was 33.0 IU/kg in these patients who were on prophylaxis.
Mediana odmerka za zdravljenje nepričakovanih krvavitev je bila 33,0 i.e./kg za tiste bolnike, ki so bili zdravljeni preventivno.
The median doses administered for the 3-week and 4-week treatment schedules were almost identical to each other (428.3 vs.
Mediani odmerki, dani v 3-tedenskem in 4-tedenskem režimu zdravljenja so bili skoraj identični (428,3 oz.
The median DR was not reached (95% CI:
Mediane DR niso dosegli (95 % IZ:
The median duration of an event was 15 days (range, 1 to 336 days), and 14 days (range, 1 to 595 days) for ALT and AST, respectively.
Mediana trajanja dogodka je znašala 15 dni (razpon 1 do 336 dni) za ALT in 14 dni (razpon 1 do 595 dni) za AST.
The median duration of blinded study treatment was 48.1 weeks (range 2 to 115) for patients receiving Votubia and 45.0 weeks (range 9 to 115) for those receiving placebo.
Mediana trajanja slepe študije je znašala 48,1 tedna (v razponu od 2 do 115) pri bolnikih, ki so prejemali zdravilo Votubia, in 45,0 tedna (v razponu od 9 do pri tistih, ki so prejemali placebo.
The median duration of blinded treatment was 40.4 weeks for patients receiving Afinitor and
Mediana trajanja slepega zdravljenja v študiji je bila 40,4 tedna pri bolnikih, ki so prejemali zdravilo Afinitor, in
The median duration of complete response was 42.1 months in the BR-CAP group compared with 18 months in the R- CHOP group.
Mediana trajanja popolnega odgovora je bila 42,1 meseca v skupini BzR-CAP in 18 mesecev v skupini R-CHOP.
The median duration of DARZALEX treatment was 3.3 months, with the longest duration of treatment being 20 months.
Mediano trajanje zdravljenja z zdravilom DARZALEX je bilo 3,3 meseca, pri čemer je najdaljše zdravljenja znašalo 20 mesecev.
The median duration of exposure to Zykadia was 33.0 weeks (range: 0.3 to 106.1 weeks).
Mediano trajanje izpostavljenosti zdravilu Zykadia je bilo 33,0 tedna (v razponu od 0,3 do 106,1 tedna).
The median duration of exposure was 171 days.
Povprečno trajanje izpostavljenosti eltrombopagu je bilo 171 dni.
The median duration of exposure was 60.5 months (range 0.1-70.8 months).
Srednja vrednost trajanja izpostavljenosti 60,5 meseca (od 0,1 do 70,8 meseca).
The median duration of exposure was 67.8 months (range 4.7 to 83.2).
Mediano trajanje izpostavljenosti je bilo 67,8 meseca (v razponu od 4,7 do 83,2).
The median duration of follow up for AURAex was 6.9 months and 6.7 months for AURA2.
V študiji AURAex je spremljanje mediano trajalo 6,9 meseca in v študiji AURA2 6,7 meseca.
The median duration of follow up was 8.2 months.
Spremljanje je trajalo mediano 8,2 meseca.
The median duration of follow-up in the Herceptin arm was 3.8 years.
Mediana spremljanja v skupini, ki je prejemala zdravilo Herceptin, je bila 3,8 let.
The median duration of follow-up of subjects (defined as date of randomization to date of last contact or death) was similar for both treatment arms (9.36 months for placebo [range 0.69 to 23.0 months] and 10.04 months for pazopanib [range 0.2 to 24.3 months].
Mediano trajanje spremljanja preiskovancev (opredeljeno kot obdobje od datuma randomizacije do datuma zadnjega stika ali smrti) je bilo v obeh terapevtskih skupinah podobno (9,36 meseca za placebo [razpon od 0,69 do 23,0 meseca] in 10,04 meseca za pazopanib [razpon od 0,2 do 24,3 meseca]).
The median duration of illness in influenza B infected subjects did not differ significantly between the treatment groups in individual studies.
Mediana časa trajanja bolezni pri bolnikih, okuženih z virusom influence tipa B, se med posameznimi skupinami v študijah ni pomembno razlikovala.
The median duration of overall survival was 29.9 months in the trastuzumab emtansine arm compared with 25.9 months in the lapatinib plus capecitabine arm.
V skupini bolnikov, ki je prejemala trastuzumab emtanzin, je bila mediana celokupnega preživetja 29,9 meseca, v primerjavi s 25,9 meseca v skupini bolnikov, ki je prejemala kombinacijo lapatiniba in kapecitabina.
The median duration of PsA disease was 5 years.
Mediano trajanje bolezni PsA je bilo 5 let.
The median duration of remission was 8.9 months, and the median relapse-free survival (RFS) was 7.6 months.
Mediana trajanja remisije je bila 8,9 mesecev in mediana preživetja brez recidiva je bila 7,6 mesecev.
The median duration of response (DOR) has not been reached.
Mediana trajanja odziva (DOR, duration of response) ni bila dosežena.
The median duration of Soliris therapy was 16 weeks (range 4 to 70 weeks) for children < 2 years of age (n=5) and 31 weeks (range 19 to 63 weeks) for children 2 to <12 years of age (n=10).
Mediana trajanja zdravljenja z zdravilom Soliris je bila 16 tednov (razpon 4 do 70 tednov) v skupini otrok, starih manj kot 2 leti (n=5), in 31 tednov (razpon 19 do 63 tednov) v skupini otrok, starih od 2 do največ 12 let (n=10).
The median duration of the longest episode was 18 days in Perjeta-treated patients and 8 days in placebo-treated patients.
Mediana trajanja najdaljše epizode je bila 18 dni v skupini bolnikov, ki je prejemala zdravilo Perjeta, in 8 dni v skupini bolnikov, ki je prejemala placebo.